Ropivacaine (rINN) (IPA: ) is a local anaesthetic drug belonging to the amino amide group. The name ropivacaine refers to both the racemate and the marketed S-enantiomer. Ropivacaine hydrochloride is commonly marketed by AstraZeneca under the trade name Naropin.
History
Ropivacaine was developed after
bupivacaine was noted to be associated with
cardiac arrest in 0.5–0.75% of cases, particularly in pregnant women. Ropivacaine was found to have less cardiotoxicity than bupivacaine in animal models.
Clinical use
Indications
Ropivacaine is indicated for local anaesthesia including infiltration,
nerve block,
epidural and
intrathecal anaesthesia in adults and children over 12 years. It is also indicated for peripheral nerve block and
caudal epidural in children 1–12 years for surgical pain. It is also sometimes used for infiltration anaesthesia for surgical pain in children.
More on
[ Ropivacaine ]